121 related articles for article (PubMed ID: 1717095)
1. Cytokeratin shedding in urine as a biological marker for bladder cancer: monoclonal antibody-based evaluation.
Helmy H; Seddek MN; Basta MT; Shaaban A; el-Baz M; el-Masry S; al-Hilaly ES; Ghoneim MA
Br J Urol; 1991 Sep; 68(3):248-53. PubMed ID: 1717095
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin shedding in urine: a biological marker for bladder cancer?
Basta MT; Attallah AM; Seddek MN; el-Mohamady H; Al-Hilaly ES; Atwaan N; Ghoneim M
Br J Urol; 1988 Feb; 61(2):116-21. PubMed ID: 2450613
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
4. UNME/K1: an IgG2a monoclonal antibody specific to cytokeratin of human urinary bladder squamous cell carcinoma.
el-Mohamady H; Basta MT; Seddek MN; Helmy H; al-Hilaly E; Attallah AM; Ghoneim MA
Urol Res; 1991; 19(2):145-50. PubMed ID: 1712997
[TBL] [Abstract][Full Text] [Related]
5. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Vigl EE; Marberger M; Pycha A
Urology; 2000 Feb; 55(2):223-6. PubMed ID: 10688083
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
8. Comparative study between cytology and dot-ELISA for early detection of bladder cancer.
Attallah AM; el-Didi M; Seif F; el-Mohamady H; Dalbagni G
Am J Clin Pathol; 1996 Jan; 105(1):109-14. PubMed ID: 8561075
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and multiparametric DNA/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinoma.
Sánchez-Carbayo M; Ciudad J; Urrutia M; Navajo JA; Orfao A
Cancer; 2001 Dec; 92(11):2811-9. PubMed ID: 11753954
[TBL] [Abstract][Full Text] [Related]
10. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
Pariente JL; Bordenave L; Michel P; Latapie MJ; Ducassou D; Le Guillou M
J Urol; 1997 Aug; 158(2):338-41. PubMed ID: 9224298
[TBL] [Abstract][Full Text] [Related]
11. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Bian W; Xu Z
Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
[TBL] [Abstract][Full Text] [Related]
12. Urinary level of CA19-9 as a tumor marker in urothelial carcinoma of the bladder.
Pal K; Roy S; Mondal SA; Chatterjee U; Tiwari P; Bera M
Urol J; 2011; 8(3):203-8. PubMed ID: 21910099
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer.
Silén A; Rizvi SS; Letocha H; Lennernäs B; Wiklund B
Oncol Rep; 2000; 7(6):1269-74. PubMed ID: 11032928
[TBL] [Abstract][Full Text] [Related]
15. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker.
Melissourgos N; Kastrinakis NG; Davilas I; Foukas P; Farmakis A; Lykourinas M
Urology; 2003 Aug; 62(2):362-7. PubMed ID: 12893365
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?
Buchumensky V; Klein A; Zemer R; Kessler OJ; Zimlichman S; Nissenkorn I
J Urol; 1998 Dec; 160(6 Pt 1):1971-4. PubMed ID: 9817302
[TBL] [Abstract][Full Text] [Related]
17. Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay.
Eissa S; Matboli M; Essawy NO; Shehta M; Kotb YM
Biomarkers; 2015; 20(3):212-7. PubMed ID: 26161701
[TBL] [Abstract][Full Text] [Related]
18. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
19. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
Lokeshwar VB; Obek C; Pham HT; Wei D; Young MJ; Duncan RC; Soloway MS; Block NL
J Urol; 2000 Jan; 163(1):348-56. PubMed ID: 10604388
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD44V2 in transitional cell carcinoma of the urinary bladder and in urine.
Müller M; Heicappell R; Habermann F; Kaufmann M; Steiner U; Miller K
Urol Res; 1997; 25(3):187-92. PubMed ID: 9228671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
